Abstract: Objective To explore the feasibility and clinical effect of BR-TRG-I type body cavity hyperthermic perfusion instrument for bladder perfusion chemotherapy in patients with non-muscular invasive bladder cancer. Methods From June 2014 to January 2015， a total of 8 non-muscle-invasive bladder cancer patients were treated with hyperthermic intravesical chemotherapy by BR-TRG-I type body cavity hyperthermic perfusion instrument in our hospital. The perfusion rate of solution was set as 200 ml／min， with the temperature of 43 ℃ for 1 hour， 1 time per week for 8 weeks， then changed to 1 time monthly. Chemotherapy drugs were selected with pirarubicin hydrochloride （THP）， 30 mg THP was dissolved in 1500 ml perfusate. Vital signs of the patients was monitored for real time during the process. Cystoscopy was performed every 3 months after TUR-BT， and the recurrence rate was observed for 2 years. Results In the process of perfusion， the BR-TRG-I type hyper thermic body cavity perfusion treatment system could achieve the continuous circulation of thermostatic perfusion， and the vital signs of the patients could keep stable. After 2 years of follow-up， all patients had no recurrence， including 2 cases of patients with voiding needling sensation， after the patients drank water， the symptoms could alleviate. Conclusion The method of bladder hyperthermic perfusion chemotherapy on non-muscle-invasive bladder cancer patients who have undergone TUR-BT proved to be an useful and effective method in prevention of non-muscle-invasive bladder cancer recurrence. The technology and methods is safe and feasible， which can achieve the continuous circulation of thermostatic perfusion， and has very bright clinical application prospect.